Evidence map›Paper›PMID 32645336›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles.

Farrokh Sharifi, Andrew Otte, Gwangheum Yoon, Kinam Park

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Release mechanisms of PLGA-based drug delivery systems: A review.International journal of pharmaceutics: X · 2025
    Article
  8. Article
  9. Long-Acting injectable buprenorphine PLGA microparticle formulation.International journal of pharmaceutics · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Farrokh SharifiPurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.
Andrew OttePurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.
Gwangheum YoonPurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA; Chong Kun Dang Research (CKD) Institute, Gyeonggi-do 16995, South Korea.
Kinam ParkPurdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA; Purdue University, Department of Pharmaceutics, West Lafayette, IN 47907, USA. Electronic address: kpark@purdue.edu.
Purdue University West Lafayette · US

Funding

Injectable naltrexone 2-month depot formulationsUH3DA048774 · NIDA · PURDUE UNIVERSITY · PI PARK, KINAM · 2022 to 2024
$4.9M
Injectable naltrexone 2-month depot formulationsUG3DA048774 · NIDA · PURDUE UNIVERSITY · PI PARK, KINAM · 2019 to 2020
$2.9M
NIDA NIH HHS UG3 DA048774NIDA NIH HHS UH3 DA048774
6 · The paper itself

Abstract

Injectable, long-acting drug delivery systems provide effective drug concentrations in the blood for up to 6 months. Naltrexone-loaded poly(lactide-co-glycolide) (PLGA) microparticles were prepared using an in-line homogenization method. It allows the transition from a laboratory scale to scale-up production. This research was designed to understand how the processing parameters affect the properties of the microparticles, such as microparticle size distributions, surface and internal morphologies, drug loadings, and drug release kinetics, and thus, to control them. The in-line homogenization system was used at high flow rates for the oil- and water-phases, e.g., 100 mL/min and 400 mL/min, respectively, to continuously generate microparticles. A high molecular weight (148 kDa) PLGA at various concentrations was used to generate oil-phases with a range of viscosities and also to compare with a 64 and 79 kDa at a single, high concentration. The uniformity of the microparticles was found to be related to the viscosity of the oil-phase. As the viscosity of the oil-phase increased from 52.6 mPa∙s to 4046 mPa∙s, the span value (a measure of uniformity) increased from 1.24 to 3.1 for the microparticles generated at the homogenization speed of 2000 RPM. Increasing the PLGA concentration from 5.58% to 16.85% showed a corresponding rise in the encapsulation efficiency from 74.0% to 85.8% and drug loading (DL) from 27.4% to 31.7% for the microparticles made with the homogenization speed of 2000 RPM. These increases may be due to a faster shell formulation, enabling PLGA microparticles to entrap more naltrexone into the structure. A higher DL, however, shortened the drug release duration from 56 to 42 days. The changes in morphology of the microparticles during different phases of the in vitro release study were also studied for three types of microparticles made with different PLGA concentrations and molecular weights. As PLGA microparticles went through structural changes, the surface showed raisin-like wrinkled morphologies within the first 10 days. Then, the microparticles swelled to form smooth surfaces. The in-line approach produced PLGA microparticles with a highly reproducible size distribution, DL, and naltrexone release rate.

Indexed as

Lactic AcidPolyglycolic AcidMicrospheresNaltrexoneParticle SizePolylactic Acid-Polyglycolic Acid CopolymerLactic AcidNaltrexonePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerDrug loadingEncapsulation efficiencyIn-line homogenizationNaltrexoneOil-phase viscosityPLGA microparticles

Identifiers

PMID32645336
PMCPMC7434690
OpenAlexW3039741565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.